LabGenius raises £35 million led by M Ventures to further develop its ML-driven antibody discovery platform and progress a pipeline of assets towards the clinic Press ReleaseLabGeniusMay 21, 2024
LabGenius’ Research Collaboration with Sanofi Yields Positive Results Press ReleaseLabGeniusSeptember 18, 2023
LabGenius Debuts T-cell Engager Optimisation Capability That Yields Molecules with >400-fold Tumour Killing Selectivity Versus Clinical Benchmark Press ReleaseLabGeniusMay 15, 2023
LabGenius Appoints Prof Hendrik-Tobias Arkenau and Prof Victor Greiff as Scientific Advisors. Press ReleaseLabGeniusApril 4, 2023
LabGenius Wins Government Innovation Grant To Support The Development Of ML-driven Cancer Therapies Press ReleaseLabGeniusNovember 30, 2022
LabGenius Appoints Dr. Leonard Wossnig as Chief Technology Officer Press ReleaseLabGeniusNovember 16, 2022
LabGenius Secures Government Innovation Grant to Expand ML-driven Drug Discovery Platform, EVA™ Press ReleaseLabGeniusOctober 7, 2022
LabGenius appoints Dr. Gino Van Heeke as Chief Scientific Officer Press ReleaseLabGeniusNovember 30, 2021
LabGenius announces research collaboration with Ablynx, a Sanofi Company Press ReleaseLabGeniusJuly 15, 2021
LabGenius closes series A extension, led by Atomico, bringing total round to $25M Press ReleaseLabGeniusOctober 29, 2020
LabGenius appoints Dr. Edwin Moses as Chairman of its Board of Directors Press ReleaseLabGeniusApril 20, 2020
